Disfunción Social
6. DISCUSIÓN DE RESULTADOS
1. Urine FSH/Cr and LH/Cr can be used as marker of ovarian reserve in patients with infertility.
45
REFERENCES
1. World Health Organization. The epidemiology of infertility report of a WHO scientific group Geneva: WHO Technical Report.1975; 582.
2. Panti AA, Sununu YT. The profile of infertility in a Teaching Hospital in North West Nigeria. Sahel Med J 2014; 17:7−11.
3. Abma JC, Chandra A, Mosher WD, Peterson LS, Piccinino LJ. Fertility, family planning, and women’s health: new data from the 1995 National Survey of Family Growth. Vital Health Stat 23. 1997;(19):1-114.
4. Soules MR, Sherman S, Parrott E, Rebar R, Santoro N, Utian W, et al. Executive summary: Stages of Reproductive Aging Workshop (STRAW). Fertil Steril. 2001;
76(5):874–8. [PubMed: 11704104]
5. Hansen KR, Thyer AC, Sluss PM, Bremner WJ, Soules MR, Klein NA.
Reproductive ageing and ovarian function: is the early follicular phase FSH rise necessary to maintain adequate secretory function in older ovulatory women? Hum Reprod. 2005;20(1):89-95.
6.
Gougeon A, Chainy GB. Morphometric studies of small follicles in ovaries of women at different ages. J Reprod Fertil. 1987; 81(2):433-4427. Faddy MJ, Gosden RG, Gougeon A, Richardson SJ, Nelson JF.Accelerated disappearance of ovarian follicles in mid-life: implications for forecasting menopause. Hum Reprod. 1992;7(10): 1342-1346.
8. Backer LC, Rubin CS, Marcus M, Kieszak SM, Schober SE. Serum follicle-stimulating hormone and luteinizing hormone levels in women aged 35–60 in the U.S population: the Third National Health and Nutrition Examination Survey (NHANES III, 1988–1994). Menopause. 1999; 6(1):29– 35. [PubMed: 10100177]
46
9. Kim YK, Wasser SK, Fujimoto VY, Klein NA, Moore DE, Soules MR. Utility of follicle stimulating hormone (FSH), luteinizing hormone (LH), oestradiol and FSH:LH ratio in predicting reproductive age in normal women. Hum Reprod. 1997;
12(6):1152–5. [PubMed: 9221992
10. Broekmans FJ, Scheffer GJ, Bancsi LF, Dorland M, Blankenstein MA, te Velde ER.
Ovarian reserve tests in infertility practice and normal fertile women. Maturitas.
1998; 30(2):205–14. [PubMed: 9871914]
11. Hansen KR, Hodnett GM, Knowlton N, Craig LB. Correlation of ovarian reserve tests with histologically determined primordial follicle number. Fertil Steril.
2011;95(1):170-175.
12. Steiner AZ, Long DL, Herring AH, Kesner JS, Meadows JW, Baird DD. Urinary Follicle-Stimulating Hormone as a Measure of Natural Fertility in a Community Cohort. Reprod Sci. 2013 May; 20(5): 549–556.
13. Scott RT, Hofmann GE. Prognostic assessment of ovarian reserve. Fertil. Steril.
1995; 63:1−11.
14. Oosterhuis GJ, Lambalk CB, Michgelsen HW, de Koning CH, Vermes I, Schoemaker J. Follicle-stimulating hormone measured in unextracted urine: a reliable tool for easy assessment of ovarian capacity. Fertil Steril. 1998;70(3):544-548.
15. Liu JH, Kao L, Rebar RW, Muse K. Urinary beta-FSH subunit concentrations in perimenopausal and postmenopausal women: a biomarker for ovarian reserve.
Menopause. 2003;10(6): 526-533.
16. Sachdev R, Von Hagen S, Kamnani A, Santoro N. Persistent pregnanediol glucuronide secretion after gonadotropin suppression indicates adrenal source of progesterone in premature ovarian failure. Hum. Reprod. 1998; 13: 2061−2063.
47
17. Van Os HC, Jansen CAM. Intercycle variation of basal FSH and improvement of IVF resluts. Hum Reprod 1992;59.
18. Filicori M, Butler JP, Crowley WF Jr. Neuroendocrine regulation of the corpus luteum in the human. Evidence for pulsatile progesterone secretion. J Clin Invest 1984;73:1638–47.
19. Ellis MJ, Donald RA, Livesey JH. Simultaneous radioimmunoassay of luteinizing hormone and follicle-stimulating hormone. J Endocrinol 1978;79:407– 8.
20. Chipman JJ, Moore RJ, Marks JF, Fevre M, Segel T, Ramsey J, et al.
Interrelationship of plasma and urinary gonadotropins: correlations for 24 hours, for sleep/wake periods, and for 3 hours after luteinizing hormone-releasing hormone stimulation. J. Clin Endocrinol Metab 1981;52:225–30.
21. Demir A, Alfthan H, Stenman UH, Voutilainen R. A clinically useful method for detecting gonadotropins in children: assessment of luteinizing hormone and follicle- stimulating hormone from urine as an alternative to serum by ultrasensitive time-resolved immunofluorometric assays. Pediatr Res 1994;36:221– 6.
22. Saketos M, Sharma N, Adel T, Raghuwanshi M, Santoro N. Timeresolved immunofluorometric assay and specimen storage conditions for measuring urinary gonadotropins. Clin Chem 1994;40:749 –53.
23. Scheffer GJ, Broekmans FJ, Looman CWN, Blankenstein M, Fauser BCJM, dejong FH, et al. The number of antral follicles in normal women with proven fertility is the best reflection of reproductive age. Hum Reprod. 2003; 18: 700−6.
24. Broekmans FJ, Kwee J, Hendriks DJ, Mol BW, Lambalk CB. A systematic review of tests predicting ovarian reserve and IVF outcome. Hum Reprod Update 2006;
12:685–718.
48
25. Markus M, Grunfeld. L, Berkowitz G, Kaplan P, Godbold J. Urine FSH as a biological marker of ovarian toxicity. Fertil. Steril 1993; 59: 931−933.
26. Baker TG. A quantitative and cytological study of germ cells in human ovaries.
Proc R Soc Lond B Biol Sci 1963;158:417–33.
27. Richardson SJ, Senikas V, Nelson JF. Follicular depletion during the menopausal transition: evidence for accelerated loss and ultimate exhaustion. J Clin Endocrinol Metab 1987; 65:1231–7.
28. Faddy MJ, Gosden RG, Gougeon A, Richardson SJ, Nelson JF. Accelerated disappearance of ovarian follicles in mid-life: implications for forecasting menopause. Hum Reprod 1992;7:1342–6.
29. Hansen KR, Knowlton NS, Thyer AC, Charleston JS, Soules MR, Klein NA. A new model of reproductive aging: the decline in ovarian non-growing follicle number from birth to menopause. Hum Reprod 2008;23:699–708.
30. Broekmans FJ, Soules MR, Fauser BC. Ovarian aging: mechanisms and clinical consequences. Endocr Rev 2009;30:465–93.
31. Johnson NP, Bagrie EM, Coomarasamy A, Bhattacharya S, Shelling AN,Jessop S, et al. Ovarian reserve tests for predicting fertility outcomes for assisted reproductive technology: the International Systematic Collaboration of Ovarian Reserve Evaluation protocol for a systematic review of ovarian reserve test accuracy. BJOG 2006;113:1472–80.
32. Klein NA, Battaglia DE, Miller PB, Branigan EF, Giudice LC, Soules MR. Ovarian follicular development and the follicular fluid hormones and growth factors in normal women of advanced reproductive age. J Clin Endocrinol Metab 1996;81:1946–51.
49
33. Klein NA, Battaglia DE, Fujimoto VY, Davis GS, Bremner WJ, Soules MR.
Reproductive aging: accelerated ovarian follicular development associated with a monotropic follicle-stimulating hormone rise in normal older women. J Clin Endocrinol Metab 1996;81:1038–45.
34. Pellestor F, Andreo B, Arnal F, Humeau C, Demaille J. Maternal aging and chromosomal abnormalities: new data drawn from in vitro unfertilized human oocytes. Hum Genet 2003; 112:195–203.
35. Volarcik K, Sheean L, Goldfarb J, Woods L, bdul-Karim FW, Hunt P. The meiotic competence of in-vitro matured human oocytes is influenced by donor age: evidence that folliculogenesis is compromised in the reproductively aged ovary. Hum Reprod 1998;13:154–60
36. Faddy MJ, Gosden RG, Gougeon A, Richardson SJ, Nelson JF.“Accelerated disappearance of ovarian follicles in mid-life: implications for forecasting menopause,” Hum Reprod. 1992;7 ( 10): 1342–1346.
37. Menken J, Trussell J, Larsen U. “Age and infertility,”Science.1986;
233.(4771):1389–1394.
38. Dunson DB, Colombo B, Baird DD. “Changes with age in the level and duration of fertility in the menstrual cycle, Hum Reprod. 2002; 17 ( 5):1399–1403.
39. Centers for Disease Control and Prevention. Assisted Reproductive Technology (ART) Report: National Summary,2009, http://apps.nccd.cdc.gov/art/Apps/National Summary Report.aspx.
40. Zegers-Hochschild F, Schwarze JE, and Galdames Eds V. Red Latinoamericana de Reproducci´on Asistida, Registro Latinoamericano de Reproducci ´on Asistida, 2008.
50
41. Steiner AZ, Paulson RJ. “Oocyte donation. Clinical Obstetrics and Gynecology.2006; 49 (1) : 44–54.
42. Broekmans FJ, Kwee J, Hendriks DJ, Mol BW, Lambalk CB. “A systematic review of tests predicting ovarian reserve and IVF outcome,” Human Reproduction Update.
2006; 12 ( 6);. 685–718.
43. Silberstein T, MacLaughlin DT, Shai I, Trimarchi JR, Lambert-Messerlian G, Seifer DB, et al., “M¨ullerian inhibiting substance levels at the time of HCG administration in IVF cycles predict both ovarian reserve and embryo morphology Hum Reproduc 2006; 21( 1) : 159–163.
44. Lambalk CB, de Koning CH. “Interpretation of elevated FSH in the regular menstrual cycle Maturitas. 1998; 30 (2): 215–220.
45. Al-Azemi M, Killick SR, Duffy S, Pye C, Refaat B, Hill N, et al. “Multi-marker assessment of ovarian reserve predicts oocyte yield after ovulation induction,”Hum Reprod 2011;26 ( 2,) :414–422.
46. Van der Steeg JW, Steures P, Eijkemans MJC, Habbema JDF, Hompes PGA, Broekmans FJ, et al. “Predictive value and clinical impact of basal follicle stimulating hormone in subfertile, ovulatory women,” J Clin Endocrinol and Metab..2007; 92 ( 6):2163–2168.
47. Haadsma ML, Groen H, Fidler V, Bukman A, Roeloffzen EMA, Groenewoud ER, et al. “The predictive value of ovarian reserve tests for spontaneous pregnancy in subfertile ovulatory women, Human Reproduction. 2008; 23( 8): 1800–1807.
48. van Montfrans JM, Hoek A, van Hooff MHA, de Koning CH, Tonch N, Lambalk CB. “Predictive value of basal follicle-stimulating hormone concentrations in a general subfertility population, Fertil. Steril.2000; 74 ( 1): 97–103.
51
49. de Carvalho BR, Rosa-E-Silva ACJDS, Rosa- E-Silva JC, Reis RMD, Ferriani RA, Silva de S´a MF. “Increased basal FSH levels as predictors of low quality follicles in infertile women with endometriosis, Inter J Gynecol Obstet.2010; 110 ( 3): 208–
212.
50. Tinkanen H, Bl¨auer M, Laippala P, Tuohimaa P, Kujansuu E. “Correlation between serum inhibin B and other indicators of the ovarian function, European Journal of Obstetrics Gynecology and Reproductive Biology.2001;94( 1):109–113.
51. Randoplh JF, Ginsburg KA, Leach RE, Blacker CM, Moghissi KS, Diamond MP, et al. Elevated early follicular gonadotropin levels in women with unexpected infertility. Fertil Steril 2003; 80 (2):320−7.
52. Kim YK, Wasser SK, Fujimoto VY, Klein NA, Moore, Soules MR: The efficacy of FSH, LH, estradiol and FSH:LH ratio in predicting reproductive age on normal women. Hum. Reprod. 1997;12 (6):1152-1155.
53. El-Toukhy T, Khalaf Y, Hart R, Taylor A, Braude P. Young age does not protect against the adverse effects of reduced ovarian reserve--an eight year study. Hum Reprod.2002; 17(6): 1519-1524.
54. Fujimoto VY, Klein NA, Battaglia DE, Bremner WJ, Soules MR. The anterior pituitary response to a gonadotropin-releasing hormone challenge test in normal older reproductive-age women. Fertil Steril.1996; 65(3): 539-544.
55. Liu JH, Koa L, Rebar RW, Muse KE. Urinary beta-FSH subunit concentrations in perimenopausal and postmenopausal women: a biomarker for ovarian reserve.
Menopause.2003; 10(6):526-33.
52
56. Oosterhuis GJE, Vermes I, Michelsen HW, Schoemaker J, Lamback CB. Follicle
stimulating hormone measured in unextracted urine throughout the menstrual cycle correlates with age and ovarian reserve. Hum Reprod. 2002; 17 (3) : 641−646.
57. Hayes FJ, Hall JE, Boepple PA, Crowley WF. Differential control of gonadotropin secretion in the human: endocrine role of inhibin,” The Journal of Clinical Endocrinology and Metabolism.1998;83 (6): 1835-1841.
58. Klein NA, Illingworth PJ, Groome NP, McNeilly AS, Battaglia DE, Soules MR.
“Decreased inhibin B secretion is associated with themonotropic FSH rise in older, ovulatory women: a study of serum and follicular fluid levels of dimeric inhibin A and B in spontaneous menstrual cycles,The Journal of Clinical Endocrinology andMetabolism.1996; 81 (7): 2742–2745.
59. Magoffin DA, Jakimiuk AJ. “Inhibin A, inhibin B and activin A in the follicular fluid of regularly cycling women,”Hum Reprod.1997;12(8): 1714–1719.
60. Welt CK, Schneyer AL. “Differential regulation of inhibin B and inhibin A by follicle-stimulating hormone and local growth factors in human granulosa cells from small antral follicles, The Journal of Clinical Endocrinology and Metabolism.2001;
86 ( 1): 330–336.
61. Tinkanen H, Bl¨auer M, Laippala P, Tuohimaa P, Kujansuu E. “Correlation between serum inhibin B and other indicators of the ovarian function,” European Journal of Obstetrics Gynecology and Reproductive Biology.2001;94(1): 109–113.
62. Seifer DB, Lambert-Messerlian G, Hogan JW, Gardiner AC, Blazar AS, Berk AC.
“Day 3 serum inhibin-B is predictive of assisted reproductive technologies outcome,” Fertility and Sterility. 1997; 67(1): 110–114.
53
63. Penarrubia J, Peralta S, F´abregues F, Carmona F, Casamitjana R, Balasch J. “Day-5 inhibin B serum concentrations and antral follicle count as predictors of ovarian response and live birth in assisted reproduction cycles stimulated with gonadotropin after pituitary suppression,” Fertility and Sterility.2010;94 (7): 2590–2595.
64. Corson SL, Gutmann J, Batzer FR, Wallace H, Klein N, Soules MR. “Inhibin-B as a test of ovarian reserve for infertile women,” Human Reproduction. 1999;14 (11):2818–2821.
65. Scheffer JB, Lozano DM, Frydman R, Fanchin R. “Relationship of serum anti-M¨ullerian hormone, inhibin B, estradiol and FSH on day 3 with ovarian follicular status,” Revista Brasileira de Ginecologia e Obstetricia.2007;29 (4):186–191.
66. McIlveen M, Skull JD, Ledger WL. “Evaluation of the utility of multiple endocrine and ultrasound measures of ovarian reserve in the prediction of cycle cancellation in a high-risk IVF population,” Human Reproduction.2007; 22 (3):778–785.
67. Broekmans FJ, Kwee J, Hendriks DJ, Mol Bw, Lambalk CB. “A systematic review of tests predicting ovarian reserve and IVF outcome,” Human Reproduction Update, vol. 12, no. 6, pp. 685–718, 2006.
68. Speroff L, Fritz MA. “Female infertility,” in Clinical Gynecologic Endocrinology and Infertility, L. Speroff and M. A. Fritz, Eds., LippincottWilliams &Wilkins, Philadelphia, Pa, USA, 7th edition, 2005; 1015−1022.
69. Frattarelli JL, Bergh PA, Drews MR, Sharara FI, Scott Jr RT. “Evaluation of basal estradiol levels in assisted reproductive technology cycles,” Fertility and Sterility.2000; 74 (3): 518–524, 2000.
70. de Carvalho BR, Rosa E Silva ACJDS, Rosa E Silva JC, R. Reis RMD, Ferriani RA, Silva De S´a MF. “Use of ovarian reserve markers and variables of response to
54
gonadotropic stimulus as predictors of embryo implantation in ICSI cycles,” Jornal Brasileiro de Reproducao Assistida, 2009;13 (3): 26−29.
71. Fanchin R, Schon¨auer LM, Righini C, Guibourdenche J, Frydman R, Taieb J.
“Serum anti-M¨ullerian hormone is more strongly related to ovarian follicular status than serum inhibin B, estradiol, FSH and LH on day 3,” Human Reproduction.2003;
18 ( 2): 323–327.
72. Visser JA, Themmen APN. “Anti-M¨ullerian hormone and folliculogenesis,”
Molecular and Cellular Endocrinology.2005; 234(12):81–86.
73. Durlinger ALL, Kramer P, Karels B, De Jong FH, Uilenbroek JTJ, Grootegoed A, et al. “Control of primordial follicle recruitment by anti-mullerian hormone in the mouse ovary,” Endocrinology.1999;140 (12): 5789–5796.
74. Visser JA, Durlinger ALL, Peters IJ, van den Heuvel ER, Rose UM, Kramer P, et al. “Increased oocyte degeneration and follicular atresia during the estrous cycle in anti-M¨ullerian hormone null mice,” Endocrinology. 2007; 148( 5): . 2301–2308.
75. Van Rooji IA, Broekmans FJ, te velde ER, Frauser BC, Bancsi LF, de Jong FH.
“Serum anti-M¨ullerian hormone levels: a novel measure of ovarian reserve,”
Human Reproduction.2002; 17 ( 12): 3065–3071.
76. Te Velde ER, Pearson PL. “The variability of female reproductive ageing,” Human Reproduction Update.2002; 8(2): 141–154, 2002.
77. Gruijters MJG, Visser JA, Durlinger ALL, Themmen APN. “Anti-M¨ullerian hormone and its role in ovarian function,”Molecular and Cellular Endocrinology.2003; 211( 1-2) 85–90.
55
78. Muttukrishna S, McGarrigle H, Wakim R, Khadum I, Ranieri DM, Serhal P.
“Antral follicle count, antimullerian hormone and inhibin B: predictors of ovarian response in assisted reproductive technology? An” International Journal of Obstetrics and Gynaecology.2005; 112(10): 1384-1390.
79. de Vet A, Laven JS, de Jong FH, Themmen APN, Fauser BCJM. “Antim¨ullerian hormone serum levels: a putative marker for ovarian aging,” Fertility and Sterility.2002;77(2):357–362.
80. Nelson SM, Messow MC, Wallace AM, Fleming R, McConnachie A. “Nomogram for the decline in serum antim¨ullerian hormone: a population study of 9,601 infertility patients,” Fertility and Sterility.2010;95( 2): 736–741.
81. Van Disseldorp J, Faddy MJ, Themmen APN, Peeters PH, van der Schouw YT, Broekmans FJ, et al. “Relationship of serum antim¨ullerian hormone concentration to age at menopause,” The Journal of Clinical Endocrinology and Metabolism.2008;93 (6):2129–2134.
82. Fanchin R, Taieb J, Lozano DHM, Ducot B, Frydman R, Bouyer J. “High reproducibility of serumanti-M¨ullerian hormone measurements suggests a multi-staged follicular secretion and strengthens its role in the assessment of ovarian follicular status,” Human Reproduction.2005; 20(4): 923–927.
83. Elgindy EA, El-Haieg DO, El-Sebaey A. “Anti-M¨ullerian hormone: correlation of early follicular, ovulatory and midluteal levels with ovarian response and cycle outcome in intracytoplasmic sperm injection patients,” Fertility and Sterility.2008;
89,(6)1670–1676.
56
84. La Marca A, Stabile G, Carducci Artenisio A, Volpe A.“Serum anti-Mullerian hormone throughout the human menstrual cycle,” Human Reproduction.2006;21 (12): 3103–3107.
85. Tsepelidis S, Devreker F, Demeestere I, Flahaut A, Gervy C, Englert Y. “Stable serum levels of anti-M¨ullerian hormone during the menstrual cycle: a prospective study in normo-ovulatory women,” Human Reproduction.2007;22 (7): 1837–1840.
86. Fadini R, Comi R, Mignini Renzini M, Coticchio G, Crippa M, De ponti E, et al.
“Antimullerian hormone as a predictive marker for the selection of women for oocyte in vitro maturation treatment,” Journal of Assisted Reproduction and Genetics.2011;28 (6): 501–508.
87. Evans AM, Petersen JW, Sekton GS, Demers R. Mapping of prolactin and tumour necrosis factor-beta gene on human chromosome 6p using lymphoblastoid cell deletion mutants. Somat cell mol Genet. 1989;15(3):203−13.
88. Bole-Feysot C, Goffin V, Edery M, Binart N, Kelly PA. Prolactin and its receptor:
actions, signal transduction pathways and phenotypes observed in prolactin receptor knock out mice. Endocr. Rev. 1998;19 (3):225−68.
89. Gerlo S, Davis JR, Mager DL, Kooljman R. prolactin in man: a tale of two promoters. Bioessays 2006;28 (10):1051−5.
90. Kiefer KA, Malarkey WB. Size heterogeneity of human prolactin in CSF and serum: experimental conditions that alter gel filtration patterns. J. Clin. Endocrinol.
Metab. 1978; 46 (1):119−24.
91. Garnier PE, Aubert ML, Kaplan SL, Grumbach MM. Heterogeneity of pituitary and plasma prolactin in man:decreased affinity of ‘’Big’’ prolactin in a radioreceptor
57
assay and evidence for its secretion. J. Clin. Endocrinol. Metab. 1978;47 (6):1273−81.
92. Kamel MA, Neulen J, Sayed GH, Salem HT, Breckwoldt M. Heterogeneity of human prolactin levels in serum during the early postpartum. Gynecol. Endocrinol.
1993; (7):173−7.
93. Mancini T, Casanueva FF, Giustina A. Hyperprolactinemia and prolactinomas.
Endocrinol. Metab Clinics of North America 2008;37 (1): 67.
94. Schwarzler P. Untergasser G, Hermann M, Dirnhofer S, Abendstein B, Berger P.
Prolactin gene expression and prolactin protein in premenopausal and postmenopausal human ovaries. Fertil. Steril. 1997; 68 (4):696−701.
95. Corona G, Mannucci E, Jannini EA, Lotti F, Ricca V, Monami M, Boddi V, et al.
Hypoprolactinemia: a new clinical syndrome in patients with sexual dysfunction.
J.sex. Med. 2009;6 (5):1457−66.
96. Corenblum B. Disorders of prolactin secretion. Eds, Copeland LJ, Jarrell JF, McGreger JA, Textbook of Gynecology Philadelphia, Pennsylvania, WB saunders company.1993: 447−467.
97. Thorner MO, and Besser GM.Prolactin Eds. Orlordan JLH. Recent advances in Endocrinology and Metabolism. 1st ed. Churchil Livingstone, Edinburg.1978:6−8.
98. Uilenbroek J. Th.J and Linden RV. Effect of prolactin on follicle oestradiol production in the rat. J. Endocrinol. 1984;102: 245−250.
99. Allen WM. The Isolation of Crystalline progestin. S cience. 1935;82(2118): 89−93.
100. Allen WM. Progesterone: how did the name originate? South Med. J. 1970; 63 (10):1151−5.
58
101. Janet EH. Clinical Assessment of ovarian function. In Harrison’s Endocrinology.2nd ed. J. Larry Jameson. McGraw-Hill Co. Inc.2010:192.
102. Nikolas P. Polyzos, Christina. I. Messini, Evangelos.G.Papanikolaou, Davide Mauri et al. Vaginal progesterone gel for luteal phase support in IVF cycles: Fertil.
Steril.2010; 94 (6):2083−2087.
103. Nigerian population census 2006. National Bureau of Statistics Official Gazatte (FGP71/52007/2,500{OL24}):4.
104. Chow SC, Shao J, Wang J. sample size calculations in clinical research.
Marcel Dekker; New York: 2003.
105. Idrisa A. infertility In. Kwawukume EY, Emuveyan EE (eds). Compresenhive Gyneacology in the tropics. Accra Graphics packing. 2005; 333−343.
106. Rebar RW, Erickson GF and Yen SSC. Fertil. Steril. 1982; 37:35.
107. Uotila M, Ruoslahti E and Engvail E. J. immunol. Methods. 1981; 42:11−15 108. Randox laboratories ltd,55 Diamond Road, Crumlin, County Antrim,BT29
4QY, United Kingdom.
109. Tsong BK, Amstrong DT, and Whitefield JF. Steroid biosynthesis by isolated human ovarian follicular cells invitro. J. Clin. Endocrinol. Metab. 1980;
51:1407−1411.
110. Autere MB, and Benson H. Progesterone: An overview and recent advances. J par. Sci. 1976; 65:783−800.
111. Cowden EA, Ratcliffe WA, Beastall GH and Ratcliffe JG. Annals Clin.
Biochem. 1979; 16: 113−121.
112. Sule J.O., P. Erigbali, L. Eruom. Prevalence of Infertility in Women in a Southwestern Nigerian Community. Afr J Biomed Res. 2008; 11:225 – 227.
59
113. Bala MA, Alfred AM, Mohammed B. Clinical presentation of infertility in Gombe, North Eastern Nigeria. Trop J Obstet Gynaecol. 2003;20: 93−96.
114. Ahmed Ebbiary NA, Lenton EA, Salt C, Ward AM, Cooked ID. The significant of elevated basal follicle stimulating hormone in regularly menstruating infertile women. Human Reprod 1994; 9 (2):245−252.
115. Lasley BL, Mobed K, Gold EB. The use of urinary hormonal assessments in human studies. Ann N Y Acad Sci 1994;709:299 –311
60 APPENDIX I
CERTIFICATE OF CONSENT
I have read the above information. I had the opportunity to ask questions about it and I have been answered to my satisfaction.
(A) I consent voluntarily to take part as a participant in this study.
( B) Name of participant………..
Signature of participant………
( C) Witness
Name ………..
Sign……… …………
Date……… … ( D) Researcher/ interviewer.
Name
……….
Sign ………
Date ………
61 APPENDIX II
QUESTIONNAIRE
I am Dr Augustine Egbagba of the Department of Chemical Pathology of the University of Benin Teaching Hospital Benin City. This questionnaire is part of a research work to assess serum FSH, LH, oestradiol, progesterone, prolactin and urinary FSH and LH in women presenting with infertility in University of Benin Teaching Hospital (UBTH). It is an academic exercise for research purpose and information given is strictly confidential.
Please fill appropriately or tick the appropriate answer.
A) PERSONAL DATA:
1.Age 18—25 yrs [ ] 26---35 yrs [ ] 36---45yrs [ ] / Actual age in years 2. Phone number………
3. Marital status: Married ] [dewodiW ] [eecroviD] [detarapeS ] [elgniS ] [ 4. Educational status: highest qualification obtained.
5. Primary [ ] secondary [ ] post secondary [ ] No formal education [ ] 6. Others (specify)……….
7. Employment status: Employed [ ] unemployed [ ] B) MEDICAL STATUS
1. Duration of marriage: 1 - 2yrs [ ] 3 - 5yrs [ ] >5yrs [ ]
2. Conception History: Never conceived [ ] conceived but miscarried [ ] parity [ ] 3. Hormonal profile: Have not done [ ] done but abnormal [ ] done and normal [ ] 4. Other investigations: Abdominal scan [ ] HSG [ ] CT scan (pelvic/brain) [ ] 5. Husband semen analysis: Normal [ ] Abnormal [ ]
6. Is your husband having another wife? Yes [ ] No [ ]
7. If yes, is she having children for your husband? Yes [ ] No [ ]
62 8. Do you have any of these conditions?
i) Diabetes Yes[ ] No [ ]
If yes, when were you diagnosed? < 5yrs [ ] 5—10 yrs [ ] >10 yrs [ ] ii) Hypertension Yes [ ] No [ ]
iii) If yes, how long were you diagnosed? < 5yrs [ ] 5—10yrs [ ] >10 yrs [ ] iv) Heart disease :Yes [ ] No [ ]
If yes, when were you diagnosed? < 5yrs [ ] 5—10 yrs [ ] >10 yrs [ ] v) What drugs/medications are you on presently?
Please
list………
vi) Do you smoke? Yes [ ] No [ ]
If yes, how long have you been smoking? <5yrs [ ] 5—10yrs [ ] >10 yrs [ ] How many cigarettes do you smoke in a day? <5 [ ] 5—10 [ ] 11—20 [ ] vii) Do you take alcohol drinks Yes [ ] NO [ ]
How long have you been drinking?...
Type of beer………
Bottles per day………
viii) Have you at anytime over bled after child birth (PPH) Yes[ ] No[ ] ix) Have you been diagnosed with STD/ PID Yes [ ] No [ ] C) PHYSICAL EXAMINATION:
1) Height……….
2)Weight………
3)Blood pressure……….
D) RESULT OF THE TESTS
Serum Urine FSH
LH